Stitched peptides as potential cell permeable inhibitors of oncogenic DAXX protein
Clare Jelinska1,2,3, Srinivasaraghavan Kannan4, Yuri Frosi5
1NTU Institute of Structural Biology, Experimental Medicine Building Level 06-01, 59 Nanyang Drive 636921 Singapore csiclar@nus.edu.sg.
Abstract:
DAXX (Death Domain Associated Protein 6) is frequently upregulated in various common cancers, and its suppression has been linked to reduced tumor progression. Consequently, DAXX has gained significant interest as a therapeutic target in such cancers. DAXX is known to function in several critical biological pathways including chromatin remodelling, transcription regulation, and DNA repair. Leveraging structural information, we have designed and developed a novel set of stapled/stitched peptides that specifically target a surface on the N-terminal helical bundle domain of DAXX. This surface serves as the anchor point for binding to multiple interaction partners, such as Rassf1C, p53, Mdm2, and ATRX, as well as for the auto-regulation of the DAXX N-terminal SUMO interaction motif (SIM). Our experiments demonstrate that these peptides effectively bind to and inhibit DAXX with a higher affinity than the known interaction partners. Furthermore, these peptides release the auto-inhibited SIM, enabling it to interact with SUMO-1. Importantly, we have developed stitched peptides that can enter cells, maintaining their intracellular concentrations at nanomolar levels even after 24 hours, without causing any membrane perturbation. Collectively, our findings suggest that these stitched peptides not only serve as valuable tools for probing the molecular interactions of DAXX but also hold potential as precursors to the development of therapeutic interventions.
Insights
Researchers developed novel stitched peptides targeting DAXX (Death Domain Associated Protein 6), a protein upregulated in cancers. These peptides inhibit DAXX, disrupt cancer progression, and show therapeutic potential.
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- DAXX (Death Domain Associated Protein 6) is upregulated in cancers, contributing to tumor progression.
- DAXX plays roles in chromatin remodeling, transcription regulation, and DNA repair.
- DAXX is a potential therapeutic target due to its role in cancer.
Purpose of the Study:
- To design and develop novel stapled/stitched peptides targeting the DAXX N-terminal helical bundle domain.
- To investigate the binding affinity and inhibitory effects of these peptides on DAXX.
- To assess the cell permeability and stability of the developed peptides.
Main Methods:
- Structure-based design of stapled/stitched peptides.
- Biochemical assays to measure peptide binding affinity and DAXX inhibition.
- Cellular assays to evaluate peptide uptake, intracellular concentration, and membrane effects.
Main Results:
- Novel peptides were designed to specifically target DAXX.
- The peptides exhibit high affinity for DAXX, exceeding that of known interaction partners.
- Peptides successfully inhibit DAXX, release its auto-inhibited SIM, and facilitate SUMO-1 interaction.
- Stitched peptides demonstrate efficient cell entry and sustained intracellular nanomolar concentrations without membrane perturbation.
Conclusions:
- Developed stitched peptides are effective DAXX inhibitors.
- These peptides serve as valuable tools for studying DAXX molecular interactions.
- The peptides show promise as a basis for developing new cancer therapeutics.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway


